Skip To Main Content
Marco De Bardi on Muck Rack

Marco De Bardi

As seen in: Nature, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marco

Contact Marco, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles - Nature Communications

|
By Francesco Millozzi, Arghya Sett, Marco De Bardi, Mario Martinez-Mingo, Maria Teresa Viscomi, Marina Bouché, Álvaro Somoza, Paula Milán-Rois, Miguel Gisbert-Garzarán, Ciro Rodríguez-Díaz, Irene Pardo, Jean-Jacques Toulmé
| Nature Verified
Abstract Inefficient targeting of muscle stem cells (MuSCs), also called satellite cells, represents a major bottleneck of current therapeutic strategies for muscular dystrophies, as it precludes the possibility of promoting compensatory regeneration.
Open in Who Shared Issue with article?

Hydrogen Sulfide Modulates Astrocytic Toxicity in Mouse Spinal Cord Cultures: Implications for Amyotrophic Lateral Sclerosis

|
By Susanna de Stefano, Marta Tiberi, Illari Salvatori, Marco De Bardi
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML - Leukemia

|
By Francesco Marchesi, Raffaele Palmieri, Adriano Venditti, Maria Teresa Voso, Daniela Francesca Angelini, Nelida Ines Noguera, Marco De Bardi, Francesco Fazi, Marco Pieraccioli, Luca Battistini
| Nature Verified
Acute Myeloid Leukemia with FLT3 internal tandem duplication mutations (FLT3-ITDmut AML) is an aggressive leukemia characterized by heterogeneous genetic landscape [1]. Despite significant advances in AML therapy, the relapse rate remains high, due to the emergence of resistant clones, possibly involving leukemic stem cells (LSCs) [2]. This highlights the unmet need for deeper understanding of the molecular and immunophenotypic landscape of LSCs in FLT3-ITDmut AML.
Open in Who Shared Issue with article?
See all 3 articles